Centella triterpenes, the primary active compounds in Centella asiatica (also known as Gotu Kola), have shown potential benefits in the management of dermatitis according to current scientific literature. These triterpenes include asiaticoside, madecassoside, asiatic acid, and madecassic acid. Several in vitro and in vivo studies suggest that Centella triterpenes possess anti-inflammatory, antioxidant, and wound-healing properties, all of which are relevant to the pathophysiology of dermatitis. For example, madecassoside has been shown to decrease pro-inflammatory cytokines and reduce histopathological changes in dermatitis models.

Clinical evidence, although limited, does exist. Small-scale human trials and case reports have indicated that topical formulations containing Centella triterpenes can help improve symptoms of eczema, atopic dermatitis, and contact dermatitis by reducing inflammation, itching, and promoting skin barrier repair. For instance, a randomized controlled trial published in the Journal of Dermatological Treatment (2017) reported that a cream containing madecassoside improved skin barrier function and reduced eczema severity in children.

While the overall body of evidence is not extensive and large-scale, high-quality clinical trials are lacking, current research provides a moderate level of scientific support for the use of Centella triterpenes in dermatitis management. Therefore, it can be considered a scientifically informed adjunctive therapy, though not a first-line treatment.